KRAS and bladder transitional cell carcinoma: Genes with a mutation frequency exceeding 20% were as follows: TTN (58.3%) and RYR2 (21.7%) in BLCA, OBSCN (21.5%) in CESC, KRAS (88.4%), TP53 (74.0%), SMAD4 (27.4%) in PAAD, TP53 (53.0%) and ATRX (21.2%) in SARC, HYDIN (45.7%), MXRA5 (39.5%), ADAM18 (27.6%), TACC2 (27.0%), EPHA6 (23.4%), FREM1 (22.0%), F8 (21.4%), XDH (21.4%), and DOCK3 (21.1%) in SKCM.